Abstract
Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in rodents. Purposeless oral movements can be elicited either by agonists or inverse agonists implying a tight control exerted by the receptor upon oral activity. The effects of agonists has been related to an action of these drugs in the subthalamic nucleus and the striatum, the two input structures for cortical efferents to the basal ganglia, a group of subcortical structures involved in the control of motor behaviors. The oral effects of agonists are dramatically enhanced in case of chronic blockade of central dopaminergic transmission induced by neuroleptics or massive destruction of dopamine neurons. The mechanisms involved in the hypersensitized oral responses to 5-HT2C agonists are not clear and deserve additional studies. Indeed, while the oral behavior triggered by 5-HT2C drugs would barely correspond to the dyskinesia observed in humans, the clinical data have consistently postulated that 5-HT2C receptors could be involved in these aberrant motor manifestations.
Keywords: Serotonin2c receptor, oral activity, neuroleptic, 6-hydroxydopamine lesion, hypersensitized oral responses
Current Neuropharmacology
Title:Serotonin2C Receptors and the Motor Control of Oral Activity
Volume: 11 Issue: 2
Author(s): Melanie Lagiere, Sylvia Navailles, Marion Bosc, Martin Guthrie and Philippe De Deurwaerdere
Affiliation:
Keywords: Serotonin2c receptor, oral activity, neuroleptic, 6-hydroxydopamine lesion, hypersensitized oral responses
Abstract: Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in rodents. Purposeless oral movements can be elicited either by agonists or inverse agonists implying a tight control exerted by the receptor upon oral activity. The effects of agonists has been related to an action of these drugs in the subthalamic nucleus and the striatum, the two input structures for cortical efferents to the basal ganglia, a group of subcortical structures involved in the control of motor behaviors. The oral effects of agonists are dramatically enhanced in case of chronic blockade of central dopaminergic transmission induced by neuroleptics or massive destruction of dopamine neurons. The mechanisms involved in the hypersensitized oral responses to 5-HT2C agonists are not clear and deserve additional studies. Indeed, while the oral behavior triggered by 5-HT2C drugs would barely correspond to the dyskinesia observed in humans, the clinical data have consistently postulated that 5-HT2C receptors could be involved in these aberrant motor manifestations.
Export Options
About this article
Cite this article as:
Lagiere Melanie, Navailles Sylvia, Bosc Marion, Guthrie Martin and Deurwaerdere De Philippe, Serotonin2C Receptors and the Motor Control of Oral Activity, Current Neuropharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570159X11311020003
DOI https://dx.doi.org/10.2174/1570159X11311020003 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy
Current Cancer Drug Targets Antimicrobial Peptide Precursor Structures Suggest Effective Production Strategies
Recent Patents on Inflammation & Allergy Drug Discovery Hepatitis C Virus NS3/4A Protease Inhibitors
Recent Patents on Anti-Infective Drug Discovery What they are, How they Work and Why they do What they do? The Story of SV40-derived Gene Therapy Vectors and What They Have to Offer
Current Gene Therapy Current Studies of Osteoclastogenesis and Potential Drug Targets
Current Drug Targets Current Technological Development of Antibody Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot Topic: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy (Guest Editor: Marie Ranson)]
Current Drug Targets Non-Nucleoside Inhibitors of NS5B Polymerase Binding to Allosteric Sites: 3DQSAR and Molecular Docking Studies
Current Medicinal Chemistry Multiclass Comparative Virtual Screening to Identify Novel Hsp90 Inhibitors: A Therapeutic Breast Cancer Drug Target
Current Topics in Medicinal Chemistry The Cell Engraftment Hypothesis of Cardiac Repair
Current Stem Cell Research & Therapy Proteasomes: A Complex Story
Current Protein & Peptide Science Some Important Dietary Polyphenolic Compounds: An Anti-inflammatory and Immunoregulatory Perspective
Mini-Reviews in Medicinal Chemistry Evolution of Reactive mPEG Polymers for the Conjugation of Peptides and Proteins
Current Organic Chemistry Platelets as Potential Link Between Diabetes and Alzheimer's Disease
Current Alzheimer Research Identification of Enzyme Inhibitors from Phage-Displayed Combinatorial Peptide Libraries
Combinatorial Chemistry & High Throughput Screening Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Current Signal Transduction Therapy Vasoproliferation and Antiproliferative Treatment Options in Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Phytochemicals for Drug Discovery in Alzheimer’s Disease: <i>In Silico</i> Advances
Current Pharmaceutical Design